Page last updated: 2024-11-13
oxytetracycline
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 54680691 |
| CHEMBL ID | 1892210 |
| SCHEMBL ID | 2898 |
| SCHEMBL ID | 23359135 |
| MeSH ID | M0015698 |
Synonyms (60)
| Synonym |
|---|
| (4s,4ar,5s,5ar,6s,12as)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide dihydrate |
| D00205 |
| terramycin (tn) |
| oxytetracycline (jan/usp/inn) |
| 6153-64-6 |
| PRESTWICK_630 |
| oxytetracycline dihydrate |
| cas-6153-64-6 |
| 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4s-(4alpha,4aalpha,5alpha,5aalpha,6beta,12aalpha))-, dihydrate |
| oxtc |
| oxytetracyclini dihydras |
| ccris 9079 |
| hydroxytetrazyklindihydrat |
| 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide dihydrate |
| oxytetracyclinium dihydricum |
| NCGC00091268-03 |
| 5-hydroxytetracycline dihydrate |
| HMS1568N16 |
| HMS2095N16 |
| dtxsid4023412 , |
| dtxcid203412 |
| tox21_300679 |
| tox21_111711 |
| NCGC00254587-01 |
| unii-x20i9en955 |
| neo-oxy 50/50 |
| x20i9en955 , |
| nsc 757262 |
| oxytetracycline [usp:inn:ban:jan] |
| 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, dihydrate, (4s,4ar,5s,5ar,6s,12as)- |
| S2052 |
| AKOS025310865 |
| oxytetracycline [jan] |
| oxytetracycline [vandf] |
| oxytetracycline dihydrate [who-dd] |
| oxytetracycline dihydrate [ep monograph] |
| oxytetracyclinum dihydras [who-ip latin] |
| oxytetracycline [green book] |
| 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,6.beta.,12a.alpha.))-, dihydrate |
| oxytetracycline [usp monograph] |
| oxytetracycline [usp-rs] |
| oxytetracycline [orange book] |
| oxytetracycline dehydrate [who-ip] |
| oxytetracycline dihydrate [green book] |
| CCG-220307 |
| SCHEMBL2898 |
| CHEMBL1892210 |
| mfcd00151234 |
| (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;dihydrate |
| (4s,4ar,5s,5ar,6s,12as,z)-2-(amino(hydroxy)methylene)-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2h,4h,5h)-trione dihydrate |
| terramycin dihydrate |
| SR-01000003006-6 |
| HMS3712N16 |
| CS-0013155 |
| HY-B0275B |
| AS-75285 |
| C75886 |
| [4s-(4alpha,4aalpha,5alpha,5aalpha,6beta,12aalpha]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide dihydrate |
| SCHEMBL23359135 |
| oxytetracycline dihydrate (injectablenon-sterile) |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (11)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 33.4983 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 39.8107 | 0.0002 | 14.3764 | 60.0339 | AID588532 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 0.1915 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 3.9151 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID588527 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 15.8489 | 0.0054 | 28.0263 | 1,258.9301 | AID720659 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 51.6556 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 24.3372 | 0.0578 | 21.1097 | 61.2679 | AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 63.0052 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 14.4525 | 0.0006 | 27.2152 | 1,122.0200 | AID720636 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 29.8493 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| microphthalmia-associated transcription factor isoform 9 | Homo sapiens (human) | IC50 (µMol) | 3.6016 | 0.0048 | 1.3710 | 4.9290 | AID1259371; AID1259373; AID1259375 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (124)
Molecular Functions (34)
Ceullar Components (19)
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347163 | 384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347164 | 384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (3)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240] | Early Phase 1 | 11 participants (Actual) | Interventional | 2014-03-06 | Terminated(stopped due to Not enough patient enrollment and lack of staffing) | ||
| A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old C [NCT03892330] | Phase 4 | 120 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| Multicenter Clinical Study,Phase III, Prospective, Randomized, Open and Comparative to Measure Tolerability and Efficacy of Taro Elixir on the Evolution Treatment of Acne Vulgaris II and III Degree or of Furunculosis Compared With Oxytetracycline [NCT01032499] | Phase 3 | 120 participants (Anticipated) | Interventional | 2010-05-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||